Innate repair receptor agonist · Also known as Cibinetide
A synthetic 11-amino-acid peptide derived from the tissue-protective region of erythropoietin (EPO). It activates the innate repair receptor to promote nerve regeneration, reduce inflammation, and protect tissues without stimulating red blood cell production.
ARA-290 was developed by Araim Pharmaceuticals to isolate the tissue-protective benefits of EPO from its blood-stimulating effects. It has been studied in phase 2 and 3 clinical trials for sarcoidosis-associated small fiber neuropathy, diabetic neuropathy, and diabetic macular edema, showing nerve fiber regeneration and pain reduction. The compound is also known by its INN name cibinetide.
The innate repair receptor (IRR) is a complex of the EPO receptor and the beta common receptor (CD131). When activated by ARA-290, it triggers an anti-inflammatory and tissue-protective cascade without stimulating erythropoiesis. This signaling suppresses pro-inflammatory cytokines, prevents neuronal and endothelial cell apoptosis, and activates reparative macrophage populations that support tissue healing.
ARA-290 also modulates the TRPV1 pain channel, directly reducing neuropathic pain signaling. In clinical studies, it promoted measurable regeneration of small nerve fibers in the cornea and skin, suggesting it does not merely mask pain but addresses the underlying nerve damage. Its anti-inflammatory effects extend to metabolic markers, with improvements in HbA1c and lipid profiles observed in diabetic patients.
4 mg/day
28 days4 mg/day
28 days (clinical trial duration)Most side effects tend to improve as your body adjusts.